AstraZeneca Acquires Fusion Pharmaceuticals for $2 Billion
AstraZeneca announced on March 19 that it entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., based in Hamilton, Canada. Fusion will become a wholly owned subsidiary of AstraZeneca, with operations continuing in Canada and the United States. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RC). Fusion’s clinical-stage development portfolio includes its lead... Read More »
AstraZeneca Acquires Amolyt Pharma From Sofinnova Partners
Sofinnova Partners announced on March 14 that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition. The transaction includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone. Amolyt Pharma is a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases. Its portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and... Read More »
AstraZeneca Picks up Vaccine Developer Icosavax for $800 Million
AstraZeneca announced on December 12 that it is acquiring Icosavax, which develops a shot for respiratory syncytial virus (RSV), for $800 million in upfront cash. The deal value equates to $15 per share. Icosavax’s shareholders will also be in line for another $5 in cash per share, if certain regulatory and sale milestones are hit. Icosavax is a clinical-stage biopharmaceutical company leveraging its virus-like particles (VLPs) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. The company’s pipeline includes a phase 3-ready protein VLP... Read More »